Ferring would like to use cookies to better understand your use of this website and improve your experience while navigating it. Please accept our use of cookies in accordance with our privacy policy. 

Accept / Decline


Ferring Canada introduces NOCDURNA®, a new treatment for Canadian adults suffering from nocturia

Toronto, Ontario, Canada, February 5, 2015 - Ferring Canada, a subsidiary of Ferring Pharmaceuticals group, today announced the availability in Canada of NOCDURNA® (desmopressin orally disintegrating tablets) for adult men and women who awaken up to four times nightly to urinate due to nocturia. Nocturia, a common and bothersome urological condition that equally affects both men and women, is characterized by the repeated need to wake to urinate at night. Nocturia is one of the leading causes of poor sleep quality and affects more than 40 percent of Canadian adults between the ages of 40 and 65 and nearly half of the elderly population.

See more Newsroom


Ferring Canada
200 Yorkland Boulevard, Suite 500
Toronto, Ontario, M2J 5C1 

Tel:  +1 416 490 0121 or +1 800 263 4057
Fax: 416 493 1692